Please assess the completion status of the following clinical trial:

Trial Title: A Study for Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus (T1DM) for at least 1 year and using insulin glargine for at least 6 months with a maximum daily dose of 1 unit per kilogram (U/kg).~* Hemoglobin A1c (HbA1c) of no greater than 10.5% before randomization~* Body mass index (BMI) 19 to 45 kilogram per square meter (kg/m²)~* Capable and willing to prepare and inject insulin with a syringe, monitor own blood glucose, complete the study diary, be receptive to diabetes education, comply with study requirements, and receive telephone calls during treatment~* Women of childbearing potential must test negative for pregnancy before receiving treatment and agree to use reliable birth control until completing the follow-up~Exclusion Criteria:~* Twice daily use of insulin glargine within 30 days prior to the study~* Use of any oral or injectable medication intended for the treatment of diabetes mellitus other than insulins in the 3 months prior to the study~* Use of an insulin pump~* More than 1 episode of severe hypoglycemia within 3 months prior to the study, or currently diagnosed as having hypoglycemia unawareness~* 2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months preceding the study~* Known hypersensitivity or allergy to any of the study insulins or their excipients~* Blood transfusion or severe blood loss within 3 months prior to the study or known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the HbA1c methodology~* Irregular sleep/wake cycle~* Pregnant or intend to become pregnant during the study~* Women who are breastfeeding~* Use of prescription or over-the-counter medications to promote weight loss within 3 months prior to the study~* Current participation in a weight loss program or plans to do so during the study~* Use of chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy currently or within 4 weeks prior to the study~* Cardiac disease with a marked impact on physical functioning~* Clinically significant electrocardiogram (ECG) abnormalities at screening~* Fasting triglycerides greater than 500 milligram per deciliter (mg/dL)~* Liver disease~* History of renal transplantation, current renal dialysis, or creatinine greater than 2.0 mg/dL (177 micromole per liter \[μmol/L\])~* Malignancy other than basal cell or squamous cell skin cancer, currently or within the last 5 years~* Treatment with any antibody-based therapy within 6 months prior to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LY2605541 First, Then Insulin Glargine (Type: EXPERIMENTAL): Participants received LY2605541 for 8 weeks, followed by insulin glargine for 8 weeks.
- Insulin Glargine First, Then LY2605541 (Type: ACTIVE_COMPARATOR): Participants received insulin glargine for 8 weeks, followed by LY2605541 for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).